IGF-1R Antibody Compositions for Treatment of Thyroid Eye Disease
Summary
The USPTO granted Patent US12595309B2 to Viridian Therapeutics, Inc. covering insulin-like growth factor-1 receptor (IGF-1R) antibody compositions and methods for treating thyroid eye disease (TED). The patent includes 23 claims directed to pharmaceutical compositions and methods of reducing proptosis and Clinical Activity Score (CAS) by inhibiting IGF-1R activity. The patent claims priority to Application No. 18942051, filed November 8, 2024.
What changed
The USPTO issued a patent grant to Viridian Therapeutics, Inc. for IGF-1R antibody compositions useful in treating thyroid eye disease, including reducing proptosis and Clinical Activity Score. The patent contains 23 claims covering antibodies targeting IGF-1R and pharmaceutical compositions for therapeutic use.
Pharmaceutical companies and biotech firms developing IGF-1R-targeted therapies for ophthalmic conditions should conduct freedom-to-operate analyses and consider potential licensing needs. Healthcare providers administering TED treatments should be aware of this newly granted intellectual property covering IGF-1R inhibition therapies.
What to do next
- Monitor patent portfolio for freedom-to-operate considerations
- Review competitive landscape for IGF-1R targeting therapies
- Assess licensing opportunities if developing similar treatments
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for treatment of thyroid eye disease
Grant US12595309B2 Kind: B2 Apr 07, 2026
Assignee
Viridian Therapeutics, Inc.
Inventors
Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
Abstract
Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS), by inhibiting the activity of IGF-1R with such antibodies and compositions.
CPC Classifications
C07K 16/2863 A61P 27/02
Filing Date
2024-11-08
Application No.
18942051
Claims
23
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.